Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies

EC Pietsch, J Dong, R Cardoso, X Zhang, D Chin… - Blood cancer …, 2017 - nature.com
CD47, a broadly expressed cell surface protein, inhibits cell phagocytosis via interaction
with phagocyte-expressed SIRPα. A variety of hematological malignancies demonstrate …

Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential

J Liu, L Wang, F Zhao, S Tseng, C Narayanan, L Shura… - PloS one, 2015 - journals.plos.org
CD47 is a widely expressed cell surface protein that functions as a regulator of phagocytosis
mediated by cells of the innate immune system, such as macrophages and dendritic cells …

[HTML][HTML] SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells

LP Ponce, NC Fenn, N Moritz, C Krupka, JH Kozik… - Oncotarget, 2017 - ncbi.nlm.nih.gov
CD47, expressed on a variety of tumor cells, confers immune resistance by delivering an
inhibitory “don't eat me” signal to phagocytic cells via its myeloid-specific receptor SIRPα …

[HTML][HTML] A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML) and high …

AM Zeidan, DJ DeAngelo, JM Palmer, CS Seet… - Blood, 2019 - Elsevier
Background: CD47 is a transmembrane protein ubiquitously expressed in human cells.
CD47 is overexpressed in various malignancies and is correlated with negative prognosis in …

Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment

S Kaur, KV Cicalese, R Banerjee… - Antibody …, 2020 - academic.oup.com
ABSTRACT CD47 is a ubiquitously expressed cell surface glycoprotein that functions as a
signaling receptor for thrombospondin-1 and as the counter-receptor for signal regulatory …

[HTML][HTML] A fully human anti-CD47 blocking antibody with therapeutic potential for cancer

D Zeng, Q Sun, A Chen, J Fan, X Yang, L Xu, P Du… - Oncotarget, 2016 - ncbi.nlm.nih.gov
CD47/SIRPα interaction serves as an immune checkpoint for macrophage-mediated
phagocytosis. Mouse anti-CD47 blocking antibodies had demonstrated potent efficacy in the …

Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody

H Ni, L Cao, Z Wu, L Wang, S Zhou, X Guo… - Cancer Immunology …, 2022 - Springer
CD47 is a widely expressed cell-surface protein that regulates phagocytosis mediated by
cells of the innate immune system, such as macrophages and dendritic cells. CD47 serves …

[HTML][HTML] CD47–SIRPα-targeted therapeutics: status and prospects

R Maute, J Xu, IL Weissman - Immuno-Oncology and Technology, 2022 - Elsevier
Highlights•CD47 is a “don't eat me” signal overexpressed on cancer cells.•Blockade of the
CD47–SIRPα signaling pathway leads to phagocytosis of tumor cells.•CD47–SIRPα …

Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding

RJ Puro, MN Bouchlaka, RR Hiebsch… - Molecular Cancer …, 2020 - AACR
Inhibitors of adaptive immune checkpoints have shown promise as cancer treatments. CD47
is an innate immune checkpoint receptor broadly expressed on normal tissues and …

The landscape overview of CD47-based immunotherapy for hematological malignancies

H Yang, Y Xun, H You - Biomarker Research, 2023 - Springer
Extensive clinical and experimental evidence suggests that macrophages play a crucial role
in cancer immunotherapy. Cluster of differentiation (CD) 47, which is found on both healthy …